Crackdown On Anti-Cancer Drugs Making Unit For Not Following Norms

Hyderabad: A drug manufacturing unit involved in production of anti-cancer injections as well as antibiotics without following the prescribed norms — was busted by the officials of Drugs Control Administration (DCA) on Wednesday.

The production unit was found making anti-cancer drug cyclophosphamide injection illegally during the raid conducted on Indian Genomix Pvt. Ltd at Cherlapally.

The company was involved in manufacturing cytotoxic, anti-cancer drugs as well as antibiotic injections. Without following the good manufacturing practices (GMPs) guidelines, these two types of drugs were being made at the same facility posing a major risk of cross-contamination of medicines. The production unit was not following the norms and thereby posing a serious health risk, DCA DG V.B. Kamalasan Reddy stated in a press statement on Wednesday.

The cytotoxic anti-cancer drug ‘cyclophosphamide injection’ alters the genetic material (DNA and RNA) of the cells and hence checks the growth or replication of cancer cells. It is used in providing chemotherapy to cancer patients and can cause severe side-effects, Kamalasan Reddy added.

The cytotoxic anti-cancer drugs should be manufactured at a separate, dedicated and self-contained production facility and as per the good manufacturing practices (GMPs) guidelines, so as to ensure a clear-cut separation of cytotoxic substances from other general drugs; otherwise ‘cross-contamination’ of general drugs with ‘cytotoxic anti-cancer drugs’ might lead to serious health consequences in a patient who is not suffering from cancer, he said.

A dedicated facility for handling cytotoxic drugs is crucial and Indian Genomix Pvt. Ltd. located at IDA Cherlapally was not following the norms while producing the anti-cancer drug. The drug manufacturing unit did have the requisite license for making anti-cancer drugs. The company was involved in manufacturing antibiotic injections, together with anti-cancer drugs posing a serious medical hazard, said the DG.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre